Polarean, Inc.

Home
United States
Durham, NC
Polarean, Inc.

Comprehensive Imaging of Lung Function in One Breath We are committed to making this capability available in your lab and putting it under your control.

Polarean has acquired the key assets and intellectual property for commercializing hyperpolarized gas MRI technology. By enabling leading academic institutions and industry scientists to freely pursue innovative ideas and applications we seek to unlock the extraordinary promise of this novel technology. Whether it’s basic physics, chemistry, or clinical imaging, our mission is to encourage adoption and exploration of hyperpolarized gas technology.

06/08/2026

The pediatric radiology community showed up in Boston, and so did the momentum. The conversations that started last week won't stop here.

IPR 2026, hosted by the The Society for Pediatric Radiology & ESPR- European Society of Paediatric Radiology, made one thing clear: the interest in functional lung imaging is real, and it is growing.

A standout moment: Katie Donohoe and colleagues at Cincinnati Children's Hospital Medical Center presented "Translating Xenon MRI into Practice: Insights from Two Years of Clinical Implementation." Hearing from a team that has brought Xenon MRI into actual clinical care for pediatric patients is exactly the kind of proof point this field needs.

The question threading through the entire meeting: how do we get more meaningful answers for children with pulmonary and cardiopulmonary disease, without adding to their radiation burden? Xenon MRI offers a path forward, with regional lung function visualization in a short, single breath-hold exam and no ionizing radiation required.

Thank you to everyone who stopped by to learn about the XENOVIEW® MRI Platform! We are proud to be part of this community and the future of pediatric lung imaging.

Every child deserves imaging that provides meaningful clinical insights, without the burden of ionizing radiation. That work is already underway.

06/02/2026

Polarean is pleased to share that Christopher von Jako, PhD, Chief Executive Officer, and Alex Dusek, Chief Business Officer, have been invited to participate in the 2nd Mayo Clinic Cardiology and Radiology Innovation Summit on June 11, 2026.

This invitation-only summit brings together Mayo Clinic key opinion leaders in cardiology, cardiac surgery, and radiology with strategic partners, investors, and selected companies focused on advancing promising healthcare innovations from concept to the patient bedside.

For Polarean, this is a meaningful opportunity to contribute to discussions on the role of functional lung imaging in cardiopulmonary disease, including how Xenon MRI may help support disease characterization, treatment planning, longitudinal monitoring, and drug development.

We are grateful to Mayo Clinic for the invitation and look forward to engaging with leaders across cardiology, radiology, innovation, and investment!

Learn more about the event here: https://metroconnections.swoogo.com/innovationsummit2026/home

06/01/2026

An exciting start to the week here in Boston ahead of the International Pediatric Radiology Congress (IPR 2026), a global event held once every five years that brings together leaders in pediatric imaging!

Before the congress, Polarean CEO Christopher von Jako and VP of Global Sales Alan Huang had the opportunity to attend Philips’ 11th Pediatric MRI User Meeting, held over the weekend at Philips North American Headquarters in Cambridge, Massachusetts.

The meeting brought together leading pediatric MRI users to discuss emerging technologies, clinical applications, and the future of pediatric imaging. A highlight was Alan Huang’s presentation on the XENOVIEW® MRI Platform. Presented to a packed room, the session sparked thoughtful discussion, excellent questions, and strong interest in the growing role of Xenon MRI in pediatric cardiopulmonary imaging.

It was especially rewarding to have clinical leaders from both Cincinnati Children's Hospital Medical Center and The Hospital for Sick Children (SickKids) in Toronto in attendance, sharing real-world experience and discussing how Xenon MRI is being used in pediatric patient care and research.

The enthusiasm surrounding multinuclear MRI and pediatric cardiopulmonary imaging was encouraging and reinforces the growing momentum behind this important field.

Thank you to the Philips team for the invitation and outstanding hospitality, especially Margriet Nijnens, Shuo Zhang, Diana Hoogenraad, and Joep van Oorschot.

Polarean is proud to partner with Philips as we work together to advance multinuclear MRI and expand access to innovative imaging solutions for children with pulmonary and cardiopulmonary disease.

05/28/2026

Pediatric patients deserve answers — with imaging that avoids ionizing radiation.

At the International Pediatric Radiology Congress 2026 next week in Boston, we’re showcasing how Xenon MRI enables regional visualization of lung function in a short, single breath-hold exam, with no ionizing radiation.

In pediatric patients with cystic fibrosis, asthma, and primary ciliary dyskinesia, Xenon MRI has detected regional functional abnormalities, including in cases where pulmonary function tests appeared normal.

📍 Heading to IPR 2026? Find us at Booth #15 and connect with our team: Alan Huang, Daniel Booker and Brady Anna.

Xenon MRI Image reference: Schmidt et al., Radiology: Cardiothoracic Imaging 2025. doi:10.1148/ryct.240562

The Society for Pediatric Radiology ESPR- European Society of Paediatric Radiology

05/26/2026

A productive visit to UVA Health, working alongside the group on our Siemens Healthineers XENOVIEW® Chest Coil evaluation and advancing the future of the XENOVIEW® MRI Platform on next-generation 3T MRI systems, including the Siemens Healthineers MAGNETOM Cima.X.

It is especially meaningful to be at UVA, widely recognized as the birthplace of human Xenon MRI and one of the pioneering institutions in the development of hyperpolarized gas MRI.

A special thank you to our own Iain Bruce, PhD, for leading the effort, and to one of our closest collaborators, Professor John Mugler, whose impact on the MRI field extends far beyond Xenon MRI. His contributions to pulmonary MRI, rapid imaging methods, and the development of advanced MRI technology have influenced generations of researchers and clinicians across the broader MRI community.

Excited to continue building on this foundation as functional lung imaging advances.

05/21/2026

What a strong week for Polarean at the International Conference in Orlando!

Our team had the opportunity to connect with clinicians, researchers, and industry partners across pulmonary medicine, imaging, and drug development.

This year, was featured in more than 20 presentations spanning pediatric lung disease, pulmonary hypertension, cardiopulmonary physiology, clinical trial endpoint development, and quantitative functional lung imaging.

We were also proud to have Alex Dusek, Polarean’s Chief Business Officer, present at the Respiratory Innovation Summit on how Xenon MRI may help accelerate cardiopulmonary drug development through noninvasive, regional biomarkers of lung function.

Thank you to everyone who connected with us at ATS and to the researchers continuing to advance the science and clinical application of Xenon MRI.

American Thoracic Society

05/13/2026

Last week, members of the Polarean team were at the National Institutes of Health (NIH) supporting ongoing work in hyperpolarized xenon gas MRI and advanced functional lung imaging.

It was great to spend time with the NIH team as they advance experimental integration of the XENOVIEW® MRI platform in combination with the 80 cm wide-bore Siemens Healthineers MAGNETOM Free.Max 0.55T MRI system for use in their pioneering research in low-field lung imaging.

The visit included technical collaboration, workflow discussions, and additional hands-on training focused on hyperpolarized gas production, system operation. It is exciting to see continued interest in expanding functional lung MRI capabilities across different MRI field strengths and clinical research environments.

We are also encouraged by the growing engagement from investigators connected to the National Heart, Lung, and Blood Institute (NHLBI) as the field continues to explore new ways to better understand regional pulmonary and cardiopulmonary disease.

A sincere thank you to the NIH and NHLBI teams for the collaboration and hospitality.

05/08/2026

Polarean is heading to the American Thoracic Society’s Respiratory Innovation Summit next weekend, followed by the ATS 2026 International Conference, where Xenon MRI will be featured in 20+ presentations.

This year’s body of work reflects the continued scientific and clinical momentum of as a cardiopulmonary biomarker platform, with applications spanning pediatric lung disease, treatment-response assessment, clinical trial design, and advanced cardiopulmonary physiology.

At RIS, Polarean Chief Business Officer Alex Dusek will present on Accelerating Cardiopulmonary Drug Development with Xenon MRI, highlighting how quantitative Xenon MRI biomarkers may support trial enrichment, endpoint development, and earlier assessment of treatment response.

Polarean Chief Scientific Officer Bastiaan Driehuys will also deliver two oral presentations at ATS focused on pulmonary hypertension monitoring and precision phenotyping in pulmonary vascular disease.

See the full listing of Xenon MRI-related presentations, including times and locations here:https://polarean.com/wp-content/uploads/2026/05/Xenon-MRI-Advances-as-a-Cardiopulmonary-Biomarker-Platform-at-2026-RIS-and-ATS-_2026-05-07.pdf

We’re looking forward to connecting with clinicians, researchers, and industry partners in Orlando!

🔔 Book time with the Polarean team: [email protected]/" rel="ugc" target="_blank">https://outlook.office.com/book/[email protected]/

05/06/2026

We’re excited to be heading to the American Thoracic Society's Respiratory Innovation Summit , where we're presenting our latest work advancing cardiopulmonary drug development with noninvasive Xenon MRI measures of treatment effects.

Polarean Chief Business Officer Alex Dusek has a featured oral presentation on how Xenon MRI functional imaging biomarkers can help accelerate the development of therapies for pulmonary hypertension, including Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), and Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF-PH).

We’re looking forward to connecting with innovators, researchers, and industry leaders working to advance the future of respiratory medicine.

Book a meeting with Polarean during RIS or ATS 2026 in Orlando here: [email protected]/" rel="ugc" target="_blank">https://outlook.office.com/book/[email protected]/

04/23/2026

New data continue to highlight how CFTR modulators like Trikafta®* are reshaping pediatric cystic fibrosis care, with advanced imaging offering an increasingly valuable perspective.

Results from the HyPOINT clinical study demonstrate that Xenon MRI metrics showed substantially larger relative improvements compared to traditional lung function metrics such as FEV₁ and lung clearance index.

These findings reinforce an important shift: as therapies improve and patients maintain near-normal spirometry, more sensitive tools are needed to detect and monitor regional lung function changes over time. Notably, imaging was able to capture treatment response even in patients with preserved lung function, where conventional measures showed minimal change.

For clinicians caring for pediatric patients, this underscores the growing role of noninvasive, radiation-free imaging in understanding disease heterogeneity, evaluating treatment response, and supporting longitudinal monitoring in the era of highly effective therapies.

Read the full article and quote by Dr. Felix Ratjen of SickKids Foundation:
https://www.healio.com/news/pulmonology/20251119/trikafta-improves-ventilation-mri-outcomes-in-pediatric-cystic-fibrosis?utm_medium=email&utm_source=rasa_io&utm_campaign=newsletter

*A registered trademark of Vertex Pharmaceuticals Incorporated

Address

2500 Meridian Pkwy Ste 175
Durham, NC
27713

Telephone

+19192067900

Website

http://www.polarean.com/

Alerts

Be the first to know and let us send you an email when Polarean, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Polarean, Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in Durham?